Although cognitive decline and brain atrophy correlate with tau fibril formation in AD1–3, finding effective therapeutics that enter the brain, enter neurons that house tau fibrils and break down the fibrils remains a challenge. This evidence concerns the gene MAPT and Brain atrophy.